Langford Vets Small Animal Referral Hospital, Langford House, Langford, Bristol BS40 5DU, UK.
Langford Vets Small Animal Referral Hospital, Langford House, Langford, Bristol BS40 5DU, UK.
Vet J. 2022 Sep;287:105884. doi: 10.1016/j.tvjl.2022.105884. Epub 2022 Aug 17.
Meningoencephalitis of unknown origin (MUO) in the dog is an inflammatory condition of the central nervous system with variable short- and long-term prognosis. Previous studies have attempted to identify risk factors for early death; however, the findings were inconsistent and prognostication and treatment selection remain difficult for cases of MUO. The aim of this study was to compare the influence of putative prognostic factors on early survival in dogs with MUO. Logistic regression was used to analyse the effect of clinical and magnetic resonance imaging (MRI) features at diagnosis and type of immune-suppressive treatment received on survival at three-time points; 7 days, 30 days, and 100 days post-diagnosis. Ninety eight dogs were included. Dogs that were obtunded at presentation had a 6.6 times increased odds of death in the first 7 days after diagnosis, a 2.1 times increased risk of death 8-30 days after diagnosis, and a 1.9 times increased risk of death 31-100 days after diagnosis. No other clinical, MRI feature, or treatment was found to have a significant influence on survival. Obtundation at presentation was found to increase risk of early euthanasia in dogs with MUO, while the addition of an IV infusion of cytarabine to immune-suppressive corticosteroid therapy (prednisolone and/or dexamethasone) at initial treatment did not improve the odds of survival at 7, 30, or 100 days after diagnosis.
犬不明来源脑膜脑炎(MUO)是一种中枢神经系统的炎症性疾病,具有不同的短期和长期预后。先前的研究试图确定导致早期死亡的风险因素;然而,研究结果不一致,MUO 病例的预后和治疗选择仍然困难。本研究旨在比较潜在预后因素对 MUO 犬早期存活的影响。采用逻辑回归分析诊断时的临床和磁共振成像(MRI)特征以及接受的免疫抑制治疗类型对诊断后 7 天、30 天和 100 天三个时间点存活的影响。共纳入 98 只犬。在诊断后第 7 天内出现意识障碍的犬,早期死亡的几率增加 6.6 倍,在诊断后第 8-30 天内死亡的风险增加 2.1 倍,在诊断后第 31-100 天内死亡的风险增加 1.9 倍。没有发现其他临床、MRI 特征或治疗方法对存活有显著影响。在 MUO 犬中,就诊时出现意识障碍会增加早期安乐死的风险,而在初始治疗时,将阿糖胞苷静脉输注添加到免疫抑制性皮质类固醇治疗(泼尼松龙和/或地塞米松)中,并没有改善诊断后 7、30 或 100 天的存活几率。